Isradipine side effects: what 554 FDA adverse event reports show

Isradipine · 13 reaction terms · 94 drug–reaction co-reports · data 2026-09-14

Drug class

Dihydropyridine Calcium Channel Blocker

FDA label (Established Pharmacologic Class) · compare the class

Who reports

554 reports · 82% serious · 65 with death outcome · 54% female

openFDA FAERS counts, all years, deduplication not applied

Used for

Hypertension Isradipine is indicated in the management of hypertension. It may be used alone or concurrently with thiazide-type diuretics.

FDA label, Indications and Usage

What it is

DESCRIPTION Isradipine is a calcium antagonist available for oral administration in capsules containing 2.5 mg or 5 mg.

FDA label, Description section

Boxed warning

None in the current label

How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 9 strongest signals

Outcome field, not a reaction 1Not in label — unassessed 8

What the badges mean

Outcome field, not a reaction Death is a report outcome, not a reaction term. It is dominated by the underlying illness; see the seriousness profile and the boxed warning instead.
Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only and flags pairs whose reports are unusually skewed by sex or come mostly from consumers rather than clinicians. 4 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show: hide coding/lab/outcome terms hide indication terms unlabeled only hide PRR-only

Reaction	Reports	PRR 95% CI · ROR · χ²/p	EBGM EB05 · IC025	Label screen	Serious-only & strata	Trial cross-check
Tubulointerstitial nephritis	19	38.5 24.7–59.9ROR 39.8 · χ² 657 / p 4e-145	37.2 EB05 25.1 · IC025 +3.5 3/3 methods agree	Not in label — unassessed	serious PRR 26.9	no trial data cached
Renal tubular necrosis	9	34.7 18.2–66.4ROR 35.3 · χ² 262 / p 3e-59	32.5 EB05 18.2 · IC025 +2.5 3/3 methods agree	Not in label — unassessed	serious PRR 24.4	no trial data cached
Posterior reversible encephalopathy syndrome	8	31.9 16.0–63.5ROR 32.3 · χ² 209 / p 9e-48	29.6 EB05 15.8 · IC025 +2.3 3/3 methods agree	Not in label — unassessed	serious PRR 22.2	no trial data cached
Hepatic encephalopathy	6	24.4 11.0–54.0ROR 24.6 · χ² 112 / p 2e-26	21.4 EB05 8.5 · IC025 +1.7 3/3 methods agree	Not in label — unassessed	serious PRR 17.1	no trial data cached
Drug-induced liver injury	15	18.4 11.2–30.4ROR 18.9 · χ² 231 / p 2e-52	17.8 EB05 11.0 · IC025 +2.7 3/3 methods agree	Not in label — unassessed	serious PRR 13.0	no trial data cached
Status epilepticus	5	16.8 7.0–40.1ROR 16.9 · χ² 59 / p 7e-15	12.3 EB05 4.1 · IC025 +1.2 3/3 methods agree	Not in label — unassessed	serious PRR 11.7	no trial data cached
Rebound effect	5	16.7 7.0–40.0ROR 16.9 · χ² 59 / p 8e-15	12.3 EB05 4.1 · IC025 +1.2 3/3 methods agree	Not in label — unassessed	serious PRR 18.8	no trial data cached
Cytokine release syndrome	5	10.0 4.2–23.8ROR 10.0 · χ² 32 / p 8e-9	6.3 EB05 2.7 · IC025 +0.9 3/3 methods agree	Not in label — unassessed	serious PRR 7.0	no trial data cached
Completed suicide (death by suicide)	8	3.6 1.8–7.2ROR 3.6 · χ² 13 / p 2e-4	3.1 EB05 1.7 · IC025 +0.4	Outcome field, not a reaction	serious PRR 2.5	no trial data cached

Trial evidence (ClinicalTrials.gov)

Trial cross-check not yet run for this drug (ClinicalTrials.gov pull covers the 800 most-reported drugs first).

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

Reaction	Reports	PRR 95% CI · ROR · χ²/p	EBGM EB05 · IC025	Label screen	Serious-only & strata	Trial cross-check
Tubulointerstitial nephritis	19	38.5 24.7–59.9ROR 39.8 · χ² 657 / p 4e-145	37.2 EB05 25.1 · IC025 +3.5 3/3 methods agree	Not in label — unassessed	serious PRR 26.9	no trial data cached
Drug-induced liver injury	15	18.4 11.2–30.4ROR 18.9 · χ² 231 / p 2e-52	17.8 EB05 11.0 · IC025 +2.7 3/3 methods agree	Not in label — unassessed	serious PRR 13.0	no trial data cached
Renal tubular necrosis	9	34.7 18.2–66.4ROR 35.3 · χ² 262 / p 3e-59	32.5 EB05 18.2 · IC025 +2.5 3/3 methods agree	Not in label — unassessed	serious PRR 24.4	no trial data cached
Completed suicide (death by suicide)	8	3.6 1.8–7.2ROR 3.6 · χ² 13 / p 2e-4	3.1 EB05 1.7 · IC025 +0.4	Outcome field, not a reaction	serious PRR 2.5	no trial data cached
Posterior reversible encephalopathy syndrome	8	31.9 16.0–63.5ROR 32.3 · χ² 209 / p 9e-48	29.6 EB05 15.8 · IC025 +2.3 3/3 methods agree	Not in label — unassessed	serious PRR 22.2	no trial data cached
Hepatic encephalopathy	6	24.4 11.0–54.0ROR 24.6 · χ² 112 / p 2e-26	21.4 EB05 8.5 · IC025 +1.7 3/3 methods agree	Not in label — unassessed	serious PRR 17.1	no trial data cached
Cytokine release syndrome	5	10.0 4.2–23.8ROR 10.0 · χ² 32 / p 8e-9	6.3 EB05 2.7 · IC025 +0.9 3/3 methods agree	Not in label — unassessed	serious PRR 7.0	no trial data cached
Rebound effect	5	16.7 7.0–40.0ROR 16.9 · χ² 59 / p 8e-15	12.3 EB05 4.1 · IC025 +1.2 3/3 methods agree	Not in label — unassessed	serious PRR 18.8	no trial data cached
Status epilepticus	5	16.8 7.0–40.1ROR 16.9 · χ² 59 / p 7e-15	12.3 EB05 4.1 · IC025 +1.2 3/3 methods agree	Not in label — unassessed	serious PRR 11.7	no trial data cached
Product physical issue	4	7.6 2.9–20.2ROR 7.7 · χ² 17 / p 2e-5	4.6 EB05 1.9 · IC025 +0.4	Reporting / coding artifact	–	no trial data cached
Pulmonary thrombosis	4	13.9 5.2–36.9ROR 14.0 · χ² 36 / p 1e-9	8.4 EB05 2.8 · IC025 +0.7 3/3 methods agree	Not in label — unassessed	serious PRR 9.8	no trial data cached
Drug exposure during pregnancy	3	3.3 1.1–10.2ROR 3.3 · χ² 3 / p 0.048	2.5 EB05 1.0 · IC025 -0.8 PRR-only: not supported by EBGM or IC	Reporting / coding artifact	serious PRR 2.6	no trial data cached
Toxic skin eruption	3	11.3 3.6–34.8ROR 11.3 · χ² 19 / p 8e-6	5.7 EB05 1.9 · IC025 +0.1	Not in label — unassessed	serious PRR 7.9	no trial data cached

Unlabeled candidate signals

Every screened signal with n ≥ 20 was either labeled, an indication term, or an artifact pattern — no unlabeled candidate stood out in the top signals.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Isradipine?

In FDA FAERS, the most frequently co-reported reaction terms for Isradipine are tubulointerstitial nephritis, drug-induced liver injury, renal tubular necrosis, posterior reversible encephalopathy syndrome, hepatic encephalopathy, cytokine release syndrome. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Isradipine have an FDA boxed warning?

No. The FDA label retrieved for Isradipine has no boxed warning; see the label's Warnings and Precautions for the recognised risks.

Do FAERS signals prove that Isradipine causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

FDA label via openFDA (set ID bf3425e0-428d-4bdb-ac9a-3b9d483df83a, effective 20231130; matched on openfda.generic_name.exact:"ISRADIPINE")
Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA count= aggregation, field patient.drug.openfda.generic_name.exact, 13 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction
Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
Seriousness and sex counts from openFDA count=serious, patient.patientsex, seriousnessdeath

Page generated 2026-10-08. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.